Search
for
Sort by
Research 151–180 of 534
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- 1313 Fzd2 controls multiple aspects of epidermal development through distinct signaling mechanisms
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Turning JAK STATic, a peek into the future of dermatology therapeutics
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Ritlecitinib: First Approval
- Janus kinase inhibitors for alopecia areata
- Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Current and future pharmacotherapy for alopecia areata
- Clinical Perspectives on Alopecia: From Hair Follicle Biology to Advanced Therapies
- Impacto del desequilibrio del microbioma del cuero cabelludo en la severidad de la alopecia areata, marcadores inflamatorios y cambios post-tratamiento
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Tofacitinib for the treatment of lichen planopilaris: A case series
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- JAK Inhibitors for Treatment of Alopecia Areata
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Novel therapies for alopecia areata: The era of rational drug development
- A review of Janus kinase inhibitor use in scarring alopecia
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- Theoretical investigation on the construction of hair follicle membranes and the transdermal drug delivery mechanisms of JAK inhibitors via distinct pathways